SPONSOR
MedSIR
Total Trials
2
Recruiting
2
Phases
Phase 2, Phase 3
Conditions studied: HER2-positive Breast CancerAdvanced Breast CancerER-positive Breast CancerHER2-negative Breast CancerESR1 Gene Mutation
NCT06172127 Phase 2
Recruiting
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
HER2-positive Breast Cancer
NCT06382948 Phase 3
Recruiting
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
Advanced Breast Cancer